

AMENDMENTS TO THE CLAIMS

The following listing of claims replaces all prior versions of claims in the application:

Listing of Claims:

1. (Currently amended) An antibody variable region comprising the amino acid sequence set forth in SEQ ID NO: 1, ~~wherein the antibody variable region (i) is capable of binding to human GD2 and, (ii) when administered to a human patient, is less immunogenic than a variable region of a mouse anti-GD2 antibody.~~
2. (Currently amended) An antibody variable region comprising the amino acid sequence set forth in SEQ ID NO: 2, ~~wherein the antibody variable region (i) is capable of binding to human GD2 and, (ii) when administered to a human patient, is less immunogenic than a variable region of a mouse anti-GD2 antibody.~~
3. (Original) The antibody variable region of claim 2 further comprising the amino acid sequence set forth in SEQ ID NO: 1.
4. (Original) The antibody variable region of claim 3, wherein the amino acid sequences are linked by a disulfide bond.
5. (Original) The antibody variable region of claim 3, wherein the amino acid sequences are linked by a peptide bond.
6. (Currently amended) An antibody variable region comprising an amino acid sequence selected from the group consisting of amino acids 1-23 of SEQ ID NO: 1, amino acids 1-25 of SEQ ID NO: 2, and amino acids 67-98 of SEQ ID NO: 2, ~~wherein the antibody variable region (i) is capable of binding to human GD2 and, (ii) when administered to a human patient, is less immunogenic than a variable region of a mouse anti-GD2 antibody.~~
7. (Original) The antibody variable region of claim 6, wherein the amino acid sequence includes amino acids 1-23 of SEQ ID NO: 1.

8. (Original) The antibody variable region of claim 6, wherein the amino acid sequence includes amino acids 1-25 of SEQ ID NO: 2.
9. (Original) The antibody variable region of claim 6, wherein the amino acid sequence includes amino acids 67-98 of SEQ ID NO: 2.
10. (Original) A polypeptide comprising the antibody variable region of claim 6 and an Fc portion comprising at least a CH2 domain.
11. (Original) The polypeptide of claim 10, wherein the Fc portion is derived from IgG1.
12. (Canceled)
13. (Canceled)
14. (Withdrawn) A method for targeting a cell with GD2 on its surface, the method comprising:

administering the antibody variable region of claim 6.
15. (Withdrawn) The method of claim 14, wherein the cell is a tumor cell.
16. (Canceled)
17. (Currently amended) ~~A~~ The fusion protein of claim 16, wherein the non-immunoglobulin moiety is comprising the antibody variable region of claim 6 and a cytokine.
18. (Original) The fusion protein of claim 17, wherein the cytokine is selected from the group consisting of an interleukin, a hematopoietic factor, a lymphokine, an interferon, and a chemokine.
19. (Previously presented) The fusion protein of claim 18, wherein the cytokine is an interleukin selected from the group consisting of interleukin-2 (IL-2) and interleukin-12 (IL-12).

20. (Withdrawn) The fusion protein of claim 18, wherein the cytokine is a granulocyte-macrophage colony stimulating factor (GM-CSF).
21. (Withdrawn) The fusion protein of claim 18, wherein the cytokine is a lymphotoxin.
22. (Withdrawn) The fusion protein of claim 18, wherein the cytokine is an interferon selected from the group consisting of interferon- α , interferon- β , and interferon- γ .
23. (Currently amended) The fusion protein of claim ~~16~~ 17 further comprising a second ~~non-immunoglobulin moiety~~ cytokine.
24. (Original) The fusion protein of claim 23, wherein the fusion protein comprises IL-2 and IL-12.
25. (Canceled)
26. (Canceled)
27. (Withdrawn) A method for targeting a cell with GD2 on its surface, the method comprising administering the antibody variable region of claim 1.
28. (Withdrawn) The method of claim 27, wherein the cell is a tumor cell.
29. (Withdrawn) The method of claim 27, wherein the antibody variable region is administered to a human patient.
30. (Withdrawn) A method of treating a human cancer patient, wherein the method comprises administering to the patient an effective amount of the antibody variable region of claim 1.
31. (Withdrawn) A method for targeting a cell with GD2 on its surface, the method comprising administering the antibody variable region of claim 2.
32. (Withdrawn) The method of claim 31, wherein the cell is a tumor cell.

33. (Withdrawn) The method of claim 31, wherein the antibody variable region is administered to a human patient.

34. (Withdrawn) A method of treating a human cancer patient, wherein the method comprises administering to the patient an effective amount of the antibody variable region of claim 2.

35. (Withdrawn) A method for targeting a cell with GD2 on its surface, the method comprising administering the polypeptide of claim 10.

36. (Withdrawn) The method of claim 35, wherein the cell is a tumor cell.

37. (Withdrawn) The method of claim 35, wherein the polypeptide is administered to a human patient.

38. (Withdrawn) A method of treating a human cancer patient, wherein the method comprises administering to the patient an effective amount of the polypeptide of claim 10.

39. (Withdrawn-currently amended) A method for targeting a cell with GD2 on its surface, the method comprising administering the fusion protein of claim ~~16~~ 17.

40. (Withdrawn) The method of claim 39, wherein the cell is a tumor cell.

41. (Withdrawn) The method of claim 39, wherein the fusion protein is administered to a human patient.

42. (Withdrawn-currently amended) A method of treating a human cancer patient, wherein the method comprises administering to the patient an effective amount of the fusion protein of claim ~~16~~ 17.

43. (Withdrawn) The method of claim 14, wherein the antibody variable region is administered to a human patient.

44. (Withdrawn) A method of treating a human cancer patient, wherein the method comprises administering to the patient an effective amount of the antibody variable region of claim 6.

45. (New) The antibody variable region of claim 1 further comprising an amino acid sequence selected from the group consisting of amino acids 1-25 of SEQ ID NO: 2 and amino acids 67-98 of SEQ ID NO: 2.

46. (New) The antibody variable region of claim 2 further comprising amino acids 1-23 of SEQ ID NO: 1.

47. (New) A fusion protein comprising the antibody variable region of claim 6.

48. (New) A therapeutic agent comprising the antibody variable region of claim 6.